Join us for a comprehensive exploration of one of cardiometabolic medicine's most puzzling phenomena. This evidence-packed episode synthesizes data from 300,000+ patients, genetic studies, and clinical trials to unravel why insulin resistance drives Lp(a) levels down while driving diabetes risk up. We examine the biological mechanism, analyze drug trial safety signals, and present a new clinical algorithm for interpreting Lp(a) results in metabolic context. Essential listening for clinicians wanting to stay ahead of the paradigm shift in preventive cardiology.

What you'll learn:
• The observational data from massive cohorts
• Genetic evidence establishing causation
• How insulin directly suppresses Lp(a) production
• Clinical trial data on Lp(a)-lowering drugs
• A practical algorithm for patient management
• Why OGTT testing may become crucial

In under two minutes, understand why a 'good' cholesterol number might be hiding bad news. This rapid-fire briefing breaks down the counterintuitive link between low Lp(a) levels and hidden diabetes risk. We explain the core paradox, the critical threshold to watch for, and the one key action you should take. Perfect for clinicians and health enthusiasts who need the essential insights fast.

Key points covered:
• Why low Lp(a) isn't always good news
• The insulin suppression mechanism
• The critical <10 nmol/L threshold
• Immediate clinical implications

- Heart disease is the #1 killer globally

- Lipoprotein(a) is a genetically inherited form of cholesterol

- 1 in 5 people have high Lp(a) — and don’t know it

- Most standard cholesterol tests don’t measure it

- One simple blood test gives you lifetime insight

- Ask your doctor for the Lp(a) test or take the quiz: bit.ly/StealthQuiz